Literature DB >> 20704104

Evaluation of a novel osteoporotic drug delivery system in vitro: alendronate-loaded calcium phosphate cement.

Zhao Jindong1, Tang Hai, Gu Junchao, Wang Bo, Bao Li, Wang Bing Qiang.   

Abstract

As a new drug delivery system, calcium phosphate cement was fabricated with different concentrations of alendronate (2, 5, 10 wt%), which is widely used to treat diseases related to bone loss. This study investigated the properties of the novel composite alendronate-loaded calcium phosphate cement in vitro, and found that the structure and chemical properties of the composites were not different from the calcium phosphate cement. However, the calcium phosphate cement set time was significantly faster compared with other groups (P<.01), and the strength of the calcium phosphate cement was significantly greater than the other groups (P<.01). The alendronate release rate from the composite increased with increase in drug concentration in the cement, and release was sustained over 21 days. The composite showed good biocompatibility in terms of the proliferation of rat mesenchymal stem cells. The alendronate-loaded calcium phosphate cement displayed satisfactory properties in vitro, which may be of benefit locally for osteoporotic bone in vivo. Copyright 2010, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20704104     DOI: 10.3928/01477447-20100625-15

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  7 in total

Review 1.  Calcium phosphate ceramic systems in growth factor and drug delivery for bone tissue engineering: a review.

Authors:  Susmita Bose; Solaiman Tarafder
Journal:  Acta Biomater       Date:  2011-11-20       Impact factor: 8.947

2.  In vitro characterisation of calcium phosphate biomaterials loaded with lidocaine hydrochloride and morphine hydrochloride.

Authors:  H Gautier; V Chamblain; P Weiss; C Merle; J M Bouler
Journal:  J Mater Sci Mater Med       Date:  2010-11-03       Impact factor: 3.896

3.  Effect of Alendronate with β - TCP Bone Substitute in Surgical Therapy of Periodontal Intra-Osseous Defects: A Randomized Controlled Clinical Trial.

Authors:  Rohini Naineni; Vishali Ravi; Dwijendra Kocherlakota Subbaraya; Jammula Surya Prasanna; Veerendranath Reddy Panthula; Rekha Rani Koduganti
Journal:  J Clin Diagn Res       Date:  2016-08-01

4.  Sequential dual-drug delivery of BMP-2 and alendronate from hydroxyapatite-collagen scaffolds for enhanced bone regeneration.

Authors:  Dongtak Lee; Maierdanjiang Wufuer; Insu Kim; Tae Hyun Choi; Byung Jun Kim; Hyo Gi Jung; Byoungjun Jeon; Gyudo Lee; Ok Hee Jeon; Hak Chang; Dae Sung Yoon
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

5.  A Biphasic Calcium Sulphate/Hydroxyapatite Carrier Containing Bone Morphogenic Protein-2 and Zoledronic Acid Generates Bone.

Authors:  Deepak Bushan Raina; Hanna Isaksson; Werner Hettwer; Ashok Kumar; Lars Lidgren; Magnus Tägil
Journal:  Sci Rep       Date:  2016-05-18       Impact factor: 4.379

Review 6.  Calcium Phosphates as Delivery Systems for Bisphosphonates.

Authors:  Adriana Bigi; Elisa Boanini
Journal:  J Funct Biomater       Date:  2018-01-13

Review 7.  Bone Diseases: Current Approach and Future Perspectives in Drug Delivery Systems for Bone Targeted Therapeutics.

Authors:  Giulia Chindamo; Simona Sapino; Elena Peira; Daniela Chirio; Mónica Cristina Gonzalez; Marina Gallarate
Journal:  Nanomaterials (Basel)       Date:  2020-05-01       Impact factor: 5.076

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.